Tesamorelin 10mg/30mg – GHRH analogue for laboratory research

What is Tesamorelin?

Tesamorelin is a synthetic, stabilized GHRH analog — the growth-hormone-releasing hormone. Structurally it is GHRH (1-44) with a trans-3-hexenoic acid modification at the N-terminus, which protects the molecule from enzymatic breakdown (including by DPP-4) and extends its action relative to native GHRH. It binds the GHRH receptor in the pituitary with high affinity and stimulates endogenous secretion of growth hormone (GH), and indirectly IGF-1.

The feature that distinguishes Tesamorelin among GHRH analogs is its selective action on visceral fat. A longer half-life (~26 min, versus ~12 min for Sermorelin) provides more sustained GHRH signaling, which in clinical trials translated into a marked reduction of visceral adipose tissue (VAT). This sets it apart from GHRH analogs directed mainly at the general GH axis, like CJC-1295.

The research-grade Tesamorelin offered by Peptology is not a medicinal product — it is a lyophilized research peptide intended exclusively for scientific and in vitro applications, not intended for use in humans or animals. In the EU it is not authorized for clinical use. See also the other recovery and anabolic peptides in our category.

In the version offered by Peptology, Tesamorelin is supplied as a lyophilized peptide with purity above 99% (HPLC/MS), confirmed by independent laboratory analysis (CoA for every batch). It is available in two vial formats — 10 mg and 30 mg — depending on the scale of the research protocol.

Available formats: 10 mg and 30 mg

Tesamorelin is available in two lyophilized formats that cover different scales of research work — from single in vitro series to longer GH-axis and lipolysis protocols with higher peptide consumption.

Both formats have identical purity > 99% and the same laboratory certificate for the batch. The choice of size depends on the scale of the protocol, not on the concentration of the active substance.

How Tesamorelin works — stabilized stimulation of the GHRH axis

In the clinical literature, Tesamorelin is described as a stabilized GHRH analog with a particular affinity for reducing visceral fat. The three features below together explain its profile — physiological, but distinctly lipolytic.

Why selectivity for visceral fat matters

Visceral fat (VAT) — surrounding the abdominal organs — is metabolically active and strongly linked to cardiometabolic risk. Thanks to sustained, physiological stimulation of the GH axis, Tesamorelin selectively reduces VAT and liver fat in studies, with only a moderate effect on lean mass. This makes it a model research tool for studying GH-dependent lipolysis and the regulation of body composition.

Like other GHRH analogs, in studies Tesamorelin is sometimes combined with a GHRP secretagogue (e.g. Ipamorelin) acting on a separate receptor, GHS-R1a. These data come from controlled clinical trials and do not constitute a claim about the effect of the research-grade product.

Pharmacokinetics and pharmacodynamics of Tesamorelin

Tesamorelin is a stabilized GHRH analog which, in the published pharmacokinetic data, is described as a molecule with a short but slightly longer-than-native-GHRH half-life — which provides sustained signaling and justifies a daily dosing schedule.

• Biological half-life: about 26 minutes (versus ~12 min for sermorelin)
• Stabilization mechanism: trans-3-hexenoic acid modification (N-terminus) → resistance to DPP-4 and proteases
• Profile of action: sustained GHRH signaling, physiological GH secretion
• Target: GHRH receptor in the pituitary (cAMP pathway)
• Research schedule: clinical protocols used 2 mg SC once daily
• Route of administration: subcutaneous (SC), per the research protocol

Tesamorelin vs CJC-1295 vs Sermorelin

The table below compares three GHRH analogs acting on the same receptor but differing in stability, profile and research focus. Tesamorelin stands out for its stabilization, longer half-life and documented effect on visceral fat. The data are scientific and comparative in nature.

Sources: phase 3 trials of tesamorelin in HIV-associated lipodystrophy and meta-analyses of randomized controlled trials; pharmacokinetic data for GHRH analogs. The table is scientific and comparative in nature and does not constitute a direct head-to-head comparison or a claim about the effect of the research-grade product.

Clinical trials of Tesamorelin

Unlike many research peptides, Tesamorelin went through a full clinical program. Below are the most important observations from the studies. They concern the pharmaceutical form and come from controlled clinical trials.

Phase 3 — HIV-associated lipodystrophy

In randomized, controlled phase 3 trials in patients with excess visceral adipose tissue in the course of HIV-associated lipodystrophy, daily administration of 2 mg of tesamorelin SC produced a significant reduction of visceral adipose tissue (VAT) — on the order of ~15–18% — along with a reduction in waist circumference and liver fat, with a moderate increase in lean mass and an improvement in the triglyceride profile.

Liver fat (NAFLD / NASH)

In subsequent studies, Tesamorelin was evaluated for the reduction of liver fat content in people with HIV and hepatic steatosis, with promising results regarding a decrease in the liver fat fraction. These directions remain the subject of further research.

Safety profile and metabolism

In meta-analyses of randomized trials, the selective effect on central fat was achieved without significant worsening of lipid parameters and — in most analyses — without a meaningful increase in risk. Because of the GH-dependent mechanism, glucose metabolism remains an important element of observation (a possible rise in blood glucose).

Note: The information on clinical trials concerns the pharmaceutical form of tesamorelin and is presented for scientific and informational purposes. It does not constitute medical advice, a recommendation for use or a claim about the effect of the research-grade product offered by Peptology.

Documented clinical results of Tesamorelin

• Stabilized GHRH analog (1-44) with a trans-3-hexenoic modification — resistant to enzymatic breakdown
• Reduction of visceral fat ~15–18% in randomized phase 3 trials in HIV lipodystrophy
• Reduction in waist circumference and liver fat and improvement in the triglyceride profile
• Selective action on central fat with a moderate increase in lean mass
• GH-dependent mechanism — in observations, control of glucose metabolism is important

All results given concern published clinical trials of the pharmaceutical form of tesamorelin and should not be interpreted as a promise of effect, an instruction for use or a claim about the effect of the research-grade product offered by Peptology.

Research dosing protocols

In the clinical program, Tesamorelin was used in a simple, daily subcutaneous schedule — without complex titration:

• Phase 3 (HIV lipodystrophy): 2 mg SC once daily as the studied therapeutic dose
• Schedule: daily administration, usually in the evening, in a simple protocol
• Alternative schedules were described (e.g. 5 days a week), but with potentially lower efficacy
• Route of administration: subcutaneous (SC), per the research protocol

Like other GHRH analogs — CJC-1295 or Sermorelin — Tesamorelin is sometimes combined in studies with a GHRP secretagogue, like Ipamorelin. These schedules are part of controlled clinical trials and do not constitute a recommendation for self-administration.

Side effects and safety

In clinical trials, Tesamorelin was generally well tolerated, with predominantly mild to moderate side effects. Because of the GH-dependent mechanism, some effects are related to the GH/IGF-1 axis (including edema, joint pain, blood glucose).

Most side effects in the studies were transient and resolved after dose adjustment. Because of the effect on glucose, blood glucose control is an important element of observation. This information is scientific in nature and does not constitute an instruction for use.

Storage and reconstitution

Tesamorelin is supplied as a lyophilized (freeze-dried) powder in a vial. In lyophilized form the peptide is stable at room temperature, protected from light and moisture — refrigeration before reconstitution is not mandatory. After reconstitution, stability depends on the solvent used, with Peptide Matrix Water™ significantly extending the peptide's lifespan.

• Before reconstitution: room temperature, in the original packaging, protected from light and moisture. A refrigerator is not mandatory.
• After reconstitution with Peptide Matrix Water™: stability in the refrigerator +2 °C to +8 °C for up to 60 days under appropriate laboratory conditions — the stabilizing formula extends the peptide's lifespan relative to standard solvents.
• After reconstitution with bacteriostatic or sterile water: stability in the refrigerator +2 °C to +8 °C for up to 28 days under appropriate conditions. Do not refreeze the reconstituted solution.
• Reconstitution: in a laboratory setting, Peptide Matrix Water™, bacteriostatic water or sterile water for injection is usually used, depending on the protocol.
• Volume: maximum 3 mL of solvent (capacity of a standard vial). For a precise calculation of volume and units, use the peptide calculator.
• Homogenization: add the solvent slowly down the vial wall, without vigorous shaking — peptide bonds are sensitive to mechanical stress. Swirl gently, do not shake.

Laboratory tip: With your order, you can add Peptide Matrix Water™ to the cart — a stabilizing solution designed for working with reconstituted research peptides. More in the article Bacteriostatic water vs acetic acid vs matrix water.

Frequently asked questions about Tesamorelin

What exactly is Tesamorelin?

It is a stabilized GHRH analog (1-44) that stimulates the pituitary to secrete growth hormone. It stands out for its selective effect on visceral fat. The results come from controlled clinical trials.

Is research-grade Tesamorelin a medicine?

No. The research-grade Tesamorelin offered by Peptology is not a registered medicine — it is a research peptide intended exclusively for scientific purposes, not for use in humans.

How does Tesamorelin differ from CJC-1295 and Sermorelin?

All are GHRH analogs acting on the same receptor. Tesamorelin is stabilized (trans-3-hexenoic modification), has a half-life of ~26 min and stands out for its documented reduction of visceral fat. CJC-1295 and Sermorelin are directed mainly at the general GH axis.

What is the half-life of Tesamorelin?

About 26 minutes — longer than native GHRH or sermorelin, thanks to stabilization with trans-3-hexenoic acid. This provides more sustained GHRH signaling and justifies a daily dosing schedule.

Which format to choose — 10 or 30 mg?

Both have identical purity > 99% and the same batch certificate. 10 mg works well for shorter protocols and single series, and 30 mg — for longer lipolysis/body-composition studies with higher peptide consumption (justified by a daily schedule).

How is Tesamorelin stored and reconstituted?

The lyophilized vial is stored at room temperature, protected from light and moisture. After reconstitution, stability depends on the solvent: with Peptide Matrix Water™ — up to 60 days in the refrigerator +2 °C to +8 °C; with bacteriostatic or sterile water — up to 28 days. Avoid refreezing.

Where to buy Tesamorelin for research?

Peptology offers Tesamorelin (10 / 30 mg) as a research peptide with confirmed purity above 99% (HPLC/MS) and independent laboratory analysis for every batch. Fast shipping, discreet packaging and certificates of purity with the product. For scientific background, also see the article Peptides — what they are, how they work, main categories and safety profile.

Related peptides in the Peptology catalog

Researchers working with Tesamorelin often also consider other GH-axis tools — GHRH analogs, GHRP secretagogues and ready-made complexes. Each of the products below has a certificate of purity above 99%:

See the full catalog: Recovery and anabolic peptides · Solutions for peptides · Blog on peptide research

Laboratory reconstitution

Laboratory protocol — reconstitution, research protocols, storage

Standardized protocol applicable to all research peptides in the Peptology catalogue. To calculate the solution concentration (mg/mL) for each vial, use the peptide reconstitution calculator.

60-second protocol

Quick reference

What you need

Five rules for reconstitution

Calculating concentration

Storage

Four mistakes to avoid

Shipping information

🚚 Shipping information

• Products in our warehouse – orders placed by 15:00 on working days are dispatched the same day, later orders on the next working day.

• Delivery with GLS to your address in 3–5 working days.

• Shipping costs €5 and is free from €50.

Frequently Asked Questions (FAQ)

In what form is Tesamorelin supplied and how should it be stored?

It is supplied as a lyophilized (freeze-dried) powder in a sealed vial. Store the unopened vial dry and protected from light, ideally at 2–8 °C. After laboratory reconstitution, keep the solution at 2–8 °C and use it within the period stated in the “Laboratory reconstitution” tab (up to 60 days with Peptide Matrix Water).

What purity does Tesamorelin have and how is it tested?

Every batch has a purity of 99% or higher, confirmed by HPLC and mass spectrometry (MS) and documented in a certificate of analysis (CoA). The report for the current batch is shown in the “Laboratory Analysis” tab.

Is a prescription required?

No. The product is offered for research use only.

Where can I buy Tesamorelin in Europe and what does it cost?

You can buy Tesamorelin in Europe online from Peptology, from 60,00 €. Delivery with GLS in 3–5 working days. Shipping is free from 50,00 €. Payment by card. Purity 99%+, with an HPLC report for every batch.

Laboratory Analysis

Tesamorelin - 10mg - Batch - 0226 - Purity

Tesamorelin - 30mg - Batch - 0226 - Purity